Market Access Consulting for Pharmaceutical and Biotechnology Companies

co.value advises pharmaceutical and biotechnology companies on market access in Germany and across Europe. Our market access consultants support AMNOG procedures from early strategic planning and G-BA consultations through dossier development and early benefit assessment to written comments, oral hearings and price negotiations.

Our work focuses on clinical evidence and the requirements of the German benefit assessment process. Our expertise includes the assessment of clinical evidence, the identification of the appropriate comparator, the evaluation of relevant endpoints, as well as statistical analyses and real-world evidence.

Consulting at the Interface Between JCA and AMNOG

co.value supports pharmaceutical and biotechnology companies in translating Joint Clinical Assessment (JCA) results into the German benefit assessment. We help assess the relevance of European evidence for the AMNOG procedure, identify national requirements and evidence gaps, and prepare the Delta Dossier for Germany.

co.value White Papers

Our white papers give you more orientation in the complex world of market access. All white papers (in German) can be requested free of charge.

  • Die Preisverhandlung von DIGA mit dem GKV-SV
  • 10 häufige Fehler im AMNOG-Verfahren
  • Advisory Board Meetings im Market Access
  • Vom Market Access zum Patient Access
  • Surrogate in der frühen Nutzenbewertung
  • Frühe Nutzenbewertung: Wie Sie vom Beratungsgespräch beim G-BA profitieren
  • Indirekte Vergleiche in der Nutzenbewertung
  • Zusammenarbeit mit ärztlichen Experten im Market Access
  • Die Value Story im Market Access

Our clients

We are hiring

co.value is growing. We offer exciting opportunities in a promising industry with the potential to work independently on customer projects. Interested?

Click here for vacancies. (German)